Cost effectiveness of influenza vaccination in patients with acute coronary syndrome in Korea |
| |
| Affiliation: | 1. Division of Licensing of Medicines and Regulatory Science, The Graduate School Pharmaceutical Management, Chung-Ang University, Seoul 06974, South Korea;2. Evidence-Based Research and Clinical Research Lab., Department of Health, Social and Clinical Pharmacy, College of Pharmacy, Chung-Ang University, Seoul 06974, South Korea;3. The Graduate School Pharmaceutical Management, Chung-Ang University, Seoul 06974, South Korea;4. Pharmaceutical Management, Economics, and Policy Lab., College of Pharmacy, Chung-Ang University, Seoul 06974, South Korea;1. University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania;2. Pittsburgh Supercomputing Center, Carnegie Mellon University, Pittsburgh, Pennsylvania;3. Department of Mathematics, Soongsil University, Seoul, South Korea;4. Department of Mathematics, University of Tulsa, Tulsa, Oklahoma;1. Institute of Infectious Diseases and Epidemiology, Tan Tock Seng Hospital, 11 Jalan Tan Tock Seng, 308433 Singapore, Singapore;2. Saw Swee Hock School of Public Health, Tahir Foundation Building, National University of Singapore, 12 Science Drive 2, #09-01, 117549 Singapore, Singapore;3. Yale-NUS College, National University of Singapore, 16 College Avenue West #01-220, 138527 Singapore, Singapore;4. School of Tropical Medicine and Global Health, Nagasaki University Institute of Tropical Medicine, 1-12-4 Sakamoto, Nagasaki 852-8523, Japan;5. London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK;6. Lee Kong Chian School of Medicine, 11 Mandalay Road, 308232 Singapore, Singapore;1. Pittsburgh Supercomputing Center, Carnegie Mellon University, Pittsburgh, PA, United States;2. Department of Family Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States;3. Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States;4. Department of Mathematics, Soongsil University, Seoul, Republic of Korea;1. China Center for Health Development Studies, Peking University, Beijing, China;2. Institute for Immunization and Prevention, Beijing Center for Disease Prevention and Control, Beijing, China;3. Beijing Chaoyang District Center for Disease Prevention and Control, Beijing, China;1. Goodnight Family Department of Sustainable Development, Appalachian State University, 222 Living Learning Center, 305 Bodenheimer Drive, Boone, NC 28608, USA;2. Emerging Pathogens Institute, P.O. Box 100009, 2055 Mowry Road, Gainesville, FL 32610, USA;3. Department of Environmental and Global Health, University of Florida, Gainesville, FL 32603, USA;5. PATH, 455 Massachusetts Ave. NW, Suite 1000, Washington, DC 20001, USA;6. PATH, 201 Westlake Avenue, Suite 200, Seattle, WA 98121, USA;1. Cardiovascular Center, Seoul National University Hospital, Seoul, Korea;2. Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea;3. National Evidence-based Healthcare Collaborating Agency, Seoul, Korea;4. Department of Information Statistics, Andong National University, Andong-si, Korea;5. School of Pharmacy, Sungkyunkwan University, Suwon-si, Korea;6. Department of Thoracic and Cardiovascular Surgery, Seoul National University Hospital and Seoul National University College of Medicine, 101 Daehak-ro, Jongro-gu, Seoul 110-744, Korea |
| |
| Abstract: | BackgroundInfluenza can cause cardiovascular abnormalities by inappropriately activating the coagulation cascade. Therefore, influenza vaccination is important because it decreases the risk of hospitalization for and mortality associated with heart disease. In particular, it reduces the occurrence of major adverse cardiovascular events (MACEs) in acute coronary syndrome (ACS) patients. Our study aimed to estimate the disease burden of MACEs and its related direct and indirect costs in ACS patients.MethodsWe estimated the direct and indirect cost of MACEs in ACS patients using a probabilistic model and the Health Insurance Review and Assessment (HIRA)-National Patient Sample (NPS) database. The effect of the influenza vaccination on the rate of MACE in ACS patients was determined using a previous systematic review and meta-analysis.ResultsOur study included 682,258 ACS patients obtained from the 2013 NPS database. According to our model, influenza vaccination would prevent 16,514 MACE-related hospitalizations and 2764 premature deaths in Korea per year. The overall reduction in costs would be $86.2 million per year from a societal perspective. Based on the results of sensitivity analysis, most of the estimated values were in the dominant area.ConclusionsOur findings show that influenza vaccination in ACS patients is highly cost effective in terms of lowering the cost of hospitalization and premature death due to MACE. Therefore, influenza vaccination is recommended as a means of relieving the clinical and socioeconomic burdens associated with ACS. |
| |
| Keywords: | Influenza vaccination Cost effectiveness Acute coronary syndrome Korea |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
